New combo therapy aims to improve leukemia remission with fewer side effects
NCT ID NCT06387121
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests a combination of low-dose chemotherapy and immune-targeted drugs in adults newly diagnosed with a specific type of leukemia (Ph-negative B-cell ALL). The goal is to see if this gentler approach can achieve deep remission (no cancer cells detectable) and improve survival. About 53 participants will receive the treatment, and researchers will monitor remission rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.